Ibrahim Nassour
Assistant Professor | University of Florida
Gainesville, FL, UNITED STATES
Dr. Ibrahaim Nassour specializes in surgeries for cancers of the gastrointestinal tract, pancreas, liver and bile duct.
Biography
Dr. Ibrahim Nassour, M.D., M.S.C.S., is an assistant professor and surgical oncologist. At UF Health, Dr. Nassour specializes in surgeries for cancers of the gastrointestinal tract, pancreas, liver and bile duct. He has special interest in robotic pancreato-biliary surgery including robotic pancreaticoduodenectomy (Whipple procedure) and in regional therapies for metastatic disease. Dr. Nassour’s research focuses on comparative effectiveness studies that evaluate the role of minimally invasive and robotic surgery as well as the role of neoadjuvant therapy in the management of pancreato-biliary cancers. In addition, he is interested in designing clinical trials in the management of pancreato-biliary malignancies.
Areas of Expertise (20)
Peritoneal Surface Malignancy
Mesothelioma
Cytroreductive Surgery
Pancreatic Pseudocyst
Neuroendocrine Tumors
Pancreatic Cancer
Ampullary Cancer
Small Bowel Cancer
GIST
Stomach Cancer
Stomach Polyp
Duodenal Cancer
Bile Duct Cancer
Cholangiocarcinoma
Colorectal Metastasis
Pancreatic Cyst
Pancreatitis
HIPEC
Carcinomatosis
Robotic Surgery
Media Appearances (1)
UF Health surgical oncologists perform first HIPEC procedure
UF Department of Surgery
2022-01-21
In December, surgeons at UF Health performed their first cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) to treat abdominal cancer in an adult patient. The surgery was successful, and the patient has been discharged and seen in clinic during the postoperative follow up.
Articles (3)
National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer
HPBIbrahim Nassour, et. al
2023-07-04
The historical standard of care in treating operable pancreatic cancer via upfront surgery has been challenged recently using a neoadjuvant approach. The aim of the study is to examine the national practice patterns in the management of pancreatic cancer with an emphasis on the trends of neoadjuvant systemic therapy use.
Novel Calculator to Estimate the Risk of Clinically Relevant Postoperative Pancreatic Fistula Following Distal Pancreatectomy
Journal of Gastrointestinal SurgeryIbrahim Nassour, et. al
2022-03-29
Drain management algorithms are based on studies that predict clinically relevant postoperative pancreatic fistula (CR-POPF) using drain fluid amylase level on POD1 (DFA1). These studies are focused on pancreaticoduodenectomy which is inherently different than distal pancreatectomy. Moreover, the change of DFA between POD1 and POD3 (ΔDFA) is underutilized despite its importance in predicting CR-POPF.
Minimally Invasive Techniques for Pancreatic Resection
Surgical Oncology ClinicsIbrahim Nassour, et. al
2021-07-21
There is increasing interest in the role of minimally invasive surgery (MIS) for pancreatectomy. Prospective data indicate significant advantages for MIS when performed for left-sided pancreatic pathologies and may be deemed as the standard of care. However, there is reluctance in implementing this technique to pancreaticoduodenectomy because of the complexity of the operation and the mixed results from randomized trials.
Social